We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a look at where ChromaDex Corp (NASDAQ:CDXC) stands against other defensive stocks that are surging in 2025.
Defensive stocks are surging as investors have been shifting their focus. Growth stocks dominated the past two years. Now, slower economic signals and rising risks are changing the landscape due to market uncertainty.
Defensive stocks offer much more stability and tend to perform well even in tough times. People still need electricity, medicine, and food. That reliability draws investors when uncertainty grows.
Many are rotating into these stocks for safety. The surge suggests a broader trend. It could mark a turning point after years of growth-led rallies., so it’s worth looking into the defensive stocks that stand out right now.
Methodology
For this article, I screened the best-performing defensive stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A laboratory technician monitoring quality control of finished dietary supplement products.
ChromaDex Corp (NASDAQ:CDXC)
Number of Hedge Fund Holders In Q4 2024: 15
ChromaDex Corp (NASDAQ:CDXC) makes dietary supplements and ingredients for healthy aging.
The stock is up significantly so far in 2025, as the company reported record-breaking results for the fourth quarter and full year of 2024. Total net sales reached $99.6 million for 2024, up 19% from the previous year.
Fourth-quarter sales alone hit $29.1 million, a 37% increase year-over-year. Tru Niagen, their flagship NAD+ supplement, led this growth with $22.7 million in Q4 sales, up 29%.
Profitability has also improved. ChromaDex posted a net income of $8.6 million for 2024, compared to a smaller profit or loss in prior years. In Q4, net income was $7.2 million. The company ended 2024 with $44.7 million in cash and no debt.
The consensus price target of $9 implies 14.78% upside.
CDXC stock is up 48.35% year-to-date.
Overall, CDXC ranks 3rd on our list of defensive stocks that are surging in 2025. While we acknowledge the potential of CDXC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CDXC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
